Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084471 | 0.87 | CASP2 (0.41) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL12248329 | 0.85 | CASP2 (0.40) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL15298766 | 0.78 | LMNA (0.47) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL31506418 | 0.78 | CNR1 (0.42) | FAAHCNR1 | |
| SCHEMBL10051008 | 0.78 | CASP2 (0.57) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL9502450 | 0.77 | CASP2 (0.71) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL1146790 | 0.77 | CASP2 (0.71) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL9518701 | 0.77 | CASP2 (0.71) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL13924359 | 0.77 | CASP2 (0.77) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL6536908 | 0.77 | LMNA (0.54) | CASP2FAAHNAAADNM1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010562-B2 | Dual molecular delivery of oligonucleotides and peptide containing conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010562-B2 | Dual molecular delivery of oligonucleotides and peptide containing conjugates | DCLRE1A, DCLRE1B, LNPEP | CASP2 3603/4885EPHX2 2055/4885FAAH 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.